PROCEPT BioRobotics Corporation PRCT R2KR3KPHARMA
Company Overview
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Why Investors Should Care
Revenue has grown at a 109.0% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.23.
Recent Developments
- Dec 2025 Revenue of $308.05M (+37.2% YoY); net profit $-95.57M.
- Trailing 12 Months Year-on-year growth — revenue +19.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 109.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 109.04% |
| 1 Year: | 19.30% |
Stock Price Performance
| 1 Year: | -43.64% |
| 6 Months: | -6.03% |
| 3 Months: | -18.22% |
| 1 Month: | +13.63% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)59.87 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 109.0% over 5 years.
CONS
- Trading 45.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PRCT PROCEPT BioRobotics Corporation R2KR3KPHARMA | 22.76 | -11.44 | $1.30B | 0.00% | -23.48% | -30.24% | 109.04% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 2.11M | 7.19M | 8.48M | 8.67M | 14.20M | 16.69M | 20.35M | 24.40M | 33.10M | 35.10M | 44.54M | 53.35M | 58.37M | 69.16M | 79.18M | 83.33M | 83.13M | 94.50M |
| Gross Profit | - | - | -31.00K | 3.53M | 3.58M | 4.24M | 7.69M | 8.49M | 10.23M | 12.49M | 18.43M | 18.87M | 25.03M | 31.48M | 36.91M | 44.16M | 51.75M | 54.01M | 53.95M | 62.38M |
| Operating Income | - | - | -10.98M | -11.34M | -13.19M | -12.80M | -15.70M | -17.88M | -22.11M | -28.38M | -25.62M | -25.61M | -27.65M | -26.83M | -22.43M | -27.44M | -22.19M | -23.19M | -32.61M | -27.39M |
| Net Income | -13.13M | -12.61M | -12.01M | -12.82M | -14.58M | -14.10M | -17.18M | -19.18M | -22.61M | -28.48M | -25.29M | -24.62M | -25.96M | -25.63M | -20.97M | -24.74M | -19.58M | -21.41M | -31.64M | -26.86M |
| Diluted EPS | - | - | -2.77 | -2.65 | -2.60 | -1.22 | -0.39 | -0.43 | -0.51 | -0.63 | -0.56 | -0.51 | -0.51 | -0.50 | -0.40 | -0.45 | -0.35 | -0.38 | -0.56 | -0.47 |
| R&D Expense | - | - | 3.89M | 4.52M | 4.48M | 4.92M | 5.01M | 6.71M | 7.58M | 10.74M | 11.61M | 11.60M | 13.08M | 17.50M | 16.65M | 16.40M | 17.63M | 18.19M | 21.46M | 20.10M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 7.72M | 34.47M | 75.01M | 136.19M | 224.50M | 308.05M |
| Gross Profit | -1.25M | 15.87M | 37.09M | 71.05M | 137.10M | 196.23M |
| Operating Income | -47.80M | -54.16M | -80.72M | -109.17M | -96.61M | -103.86M |
| Net Income | -53.02M | -59.85M | -87.15M | -105.90M | -91.41M | -95.57M |
| Diluted EPS | -14.47 | -3.63 | -1.96 | -2.24 | -1.75 | -1.72 |
| R&D Expense | 16.27M | 18.99M | 28.98M | 48.45M | 62.30M | 71.28M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 125.97M | 337.02M | 309.33M | 404.72M | 534.02M | 508.08M |
| Total Equity | -143.84M | -182.89M | 267.09M | 197.07M | 280.75M | 402.22M | 365.87M |
| Cash & Equivalents | - | 100.13M | 304.32M | 221.86M | 257.22M | 333.73M | 286.50M |
| Long Term Debt | - | 44.41M | 50.00M | 51.21M | 51.34M | 51.47M | 51.62M |
| Total Liabilities | - | 65.01M | 69.93M | 112.26M | 123.97M | 131.80M | 142.21M |
| Current Liabilities | - | 14.53M | 16.24M | 35.29M | 45.93M | 53.13M | 65.80M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -48.34M | -57.33M | -80.38M | -108.00M | -99.21M | -48.98M |
| Investing Cash Flow | -233.00K | -592.00K | -2.65M | -25.21M | -4.41M | -9.36M |
| Financing Cash Flow | 106.77M | 262.12M | 3.61M | 167.79M | 180.12M | 11.19M |
| Capital Expenditure | -233.00K | -592.00K | -2.65M | -25.21M | -4.41M | -9.36M |
| Free Cash Flow | -48.58M | -57.93M | -83.03M | -133.21M | -103.62M | -58.34M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | -16.3% | 46.0% | 49.4% | 52.2% | 61.1% | 63.7% |
| Operating Margin % | -619.4% | -157.1% | -107.6% | -80.2% | -43.0% | -33.7% |
| Net Margin % | -687.0% | -173.6% | -116.2% | -77.8% | -40.7% | -31.0% |
| ROE % | 29.0% | -22.4% | -44.2% | -37.7% | -22.7% | -26.1% |
| ROCE % | -42.9% | -16.9% | -29.5% | -30.4% | -20.1% | -23.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.50% | 4.87M | $101.44M |
| 2 | T. Rowe Price Investment Management, Inc. | 5.70% | 3.27M | $68.02M |
| 3 | BNP Paribas Asset Management Holding S.A. | 4.93% | 2.82M | $58.82M |
| 4 | Vanguard Portfolio Management LLC | 4.41% | 2.53M | $52.63M |
| 5 | Vanguard Capital Management LLC | 4.30% | 2.46M | $51.26M |
| 6 | Chicago Capital, LLC | 3.62% | 2.07M | $43.19M |
| 7 | State Street Corporation | 2.82% | 1.62M | $33.69M |
| 8 | Geode Capital Management, LLC | 2.59% | 1.48M | $30.92M |
| 9 | FMR, LLC | 2.52% | 1.44M | $30.10M |
| 10 | Price (T.Rowe) Associates Inc | 2.33% | 1.33M | $27.75M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PRCT
PRCT Shareholder Alert: PROCEPT BIOROBOTICS CORPORATION Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt - PR Newswire
<a href="https://news.google.com/rss/articles/CBMilwJBVV95cUxOMWxTNVlTaDhRcW1rMGlUM0ZZU3BJZnJhTjRfX2Rjc3VmaGRtUEVFRVhKSm1QWW5jSzdYYkU3MXNYWEhpR2JPUF9CT1R3dU5TLWRxNDhIS21CYmRNZG5yMEthc1dpRHdLbFIxZ3FFdmJyMHROLUNDRGJkakRtUDQ5QkdJeFNLaktfSEpzTH…
PROCEPT BioRobotics (PRCT) Stock Sees Fair Value Falls As Analysts Cut Growth Views - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNMkVJNXJuRmdYOU43WHZuRnZMMzZ0V1NKTlpMaFJKYnVoWDRBY1dlN2F1NUZHVTBiUDNab1ZpRXRWRWQ1S1ktdGdGSlRSeDRIUTRIU3RNRkM2dWxhOHlsQTVQejNsWXJfMUN4c2dyc2g2d0ZON2FqODJIOUM4eTRIUldxdi1pVjViYlJqN0…
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2026 in PROCEPT BIOROBOTICS CORPORATION Lawsuit - PRCT - Morningstar
<a href="https://news.google.com/rss/articles/CBMinwJBVV95cUxQZURTYXJmdEhDdy1xWnJBSGZqOFE5NHpQNHlINmloUHJJOFFFS1BKTndTMzg5V1pWaTNrQnV4TnRubm9xZ05CbGtNZnNkdUNON04teTBKVkIyLUF5TnJnVHVqMW1pekJOWkVlcGdfOGJuQW05SzVhZ0xmUlBWTTV1c0NWQ3NmMmVBTWhzNj…
PROCEPT BioRobotics Corp (PRCT) Stock Up 5.1% and Still Underval - GuruFocus
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOSlJDOF9zYzJMbXZNRnZHendiUGVVeWN3N2taLUM0TkVWT0ZTV0kyTzlYZkRySjJRcjhpbG1TcG05YkYtUGlHWkZFV0k0c2pXMGxsbWJzclNyMWZMQlY2cTktNVhYMl96WkZzZmR0bU5mYUt5Tjdoa0NQQ2VOa29NVW1laVZkcGtfTjBNQl…
PROCEPT BioRobotics Faces Investor Lawsuit - stl.news
<a href="https://news.google.com/rss/articles/CBMickFVX3lxTE5xaFlvQkpjeGN6X1ozNzdMREFsX1dJbC1OazNsbjJkUkxkUE1Ia1NiR3dqMFZZSGEtV25JLUs5M1FGREVEUmwzM3A5enlDMnNGLW03Zlp1dnpnTUlZbGhlUFpsYlQyTVBicWIxTWNkZlJfZw?oc=5" target="_blank">PROCEPT BioRo…
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMiyAJBVV95cUxNX1ltU1FwTW1CVkFRRHVvcG9iNzg1LTY5OWotVlNVY1JlNndwS3ZHQXlaV09ETVpUY3ktVDROdEZlZlZlYW9ZS1hRSXM1TlVweGlybEVMYWRRQ2ZOOFBDeU5iOF9od3FyR1JPc254RzFhV0x4SU5NV3g5bnBrODBWeGVYRVNhcmNUQ1dhMT…
PRCT — Frequently Asked Questions
What is the current share price of PROCEPT BioRobotics Corporation (PRCT)?
As of 2026-09-07 16:24 PDT, PROCEPT BioRobotics Corporation (PRCT) trades at $22.76 on NasdaqGM. Its 52-week range is $16.69 to $41.59.
What is the market capitalisation of PRCT?
PROCEPT BioRobotics Corporation (PRCT) has a market capitalisation of $1.30B on NasdaqGM.
What is the P/E ratio of PRCT?
PRCT trades at a trailing price-to-earnings (P/E) ratio of -11.44. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.34.
What is the return on equity (ROE) of PRCT?
PRCT has a return on equity (ROE) of -30.24%. Its return on capital employed (ROCE) is -23.48%.
Is PRCT a good stock to buy?
This page provides a data-driven analysis of PROCEPT BioRobotics Corporation (PRCT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.